Food and Drug Administration

Science Board for the Food and Drug Administration

November 5, 2004

Slides

CDER Critical Path Opportunities, Dr. Douglas Throckmorton, MD, FDA (HTM) (PPT)

Critical Path Opportunities for Biologics Products, Dr. Jesse Goodman, MD, MPH & Dr. Kathryn Carbone, MD, FDA (HTM) (PPT)

Critical Path Research: Getting New Technology From Bench to Bedside - A Device Perspective, Dan Schultz, FDA (HTM) (PPT)

Critical Path Public Docket: Overview for the FDA Science Board, Dr. Rovin, FDA (HTM) (PPT)

Current Plan for Critical Path Initiative, Dr. Janet Woodcock, MD, FDA (HTM) (PPT)

Stimulating Medical Innovation , HHS Task Force, Dr. Larry Kessler, ScD, FDA (HTM) (PPT)

"Critical Path" for Food and Nutrition, Alan Rulis, FDA (HTM) (PPT)

Report on "Pharmaceutical GMPs for the 21st Century" Initiative, Dr. Janet Woodcock, MD, FDA (HTM) (PPT)

Final Report on Process Analytical Technology (PAT) and Manufacturing Science, Dr. Ajaz Hussain, PhD, FDA (HTM) (PPT)

Office of Regulatory Affairs Science Peer Review - Pesticide and Industrial Chemical Programs, John Marzilli & Dr. John Specchio, PhD, FDA (HTM) (PPT)

CDER Risk-Based Site Selection Model: An FDA Risk Management Tool, Dr. Kara Morgan, PhD, FDA (HTM) (PPT)